SH-4-54

CAS No. 1456632-40-8

SH-4-54( SH-4-54 | SH 4-54 | SH4-54 | SH-454 | SH 454 | SH454. )

Catalog No. M11971 CAS No. 1456632-40-8

A potent, BBB permeable, nonphosphorylated STAT3 inhibitor that strongly binds to STAT3 protein with Kd of 300 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 55 In Stock
5MG 87 In Stock
10MG 147 In Stock
25MG 295 In Stock
50MG 475 In Stock
100MG 692 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SH-4-54
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, BBB permeable, nonphosphorylated STAT3 inhibitor that strongly binds to STAT3 protein with Kd of 300 nM.
  • Description
    A potent, BBB permeable, nonphosphorylated STAT3 inhibitor that strongly binds to STAT3 protein with Kd of 300 nM; potently kills glioblastoma brain cancer stem cells (BTSCs) and effectively suppresses STAT3 phosphorylation and its downstream transcriptional targets at low nM concentrations; potently suppresses glioma tumor growth, and inhibits pSTAT3 in vivo.(In Vitro):SH-4-54 potently kills glioblastoma brain cancer stem cells (BTSCs) and effectively suppresses STAT3 phosphorylation and its downstream transcriptional targets at low nM concentrations.SH-4-54 shows unprecedented cytotoxicity in human BTSCs, displays no toxicity in human fetal astrocytes, potently suppresses pSTAT3 with nanomolar IC50s, inhibiting STAT3's downstream targets, and shows no discernible off-target effects at therapeutic doses.(In Vivo):SH-4-54 exhibits blood-brain barrier permeability potently controls glioma tumor growth, and inhibits pSTAT3 in vivo. SH-4-54 demonstrates the power of STAT3 inhibitors for the treatment of BTSCs and validates the therapeutic efficacy of a STAT3 inhibitor for GBM clinical application.SH-4-54 decreases pSTAT3 expression in tumor cells of treated mice. SH-4-54 appears to decrease proliferation and increase apoptosis of treated tumors.
  • In Vitro
    SH-4-54 potently kills glioblastoma brain cancer stem cells (BTSCs) and effectively suppresses STAT3 phosphorylation and its downstream transcriptional targets at low nM concentrations.SH-4-54 shows unprecedented cytotoxicity in human BTSCs, displays no toxicity in human fetal astrocytes, potently suppresses pSTAT3 with nanomolar IC50s, inhibiting STAT3's downstream targets, and shows no discernible off-target effects at therapeutic doses.
  • In Vivo
    SH-4-54 exhibits blood-brain barrier permeability potently controls glioma tumor growth, and inhibits pSTAT3 in vivo. SH-4-54 demonstrates the power of STAT3 inhibitors for the treatment of BTSCs and validates the therapeutic efficacy of a STAT3 inhibitor for GBM clinical application.SH-4-54 decreases pSTAT3 expression in tumor cells of treated mice. SH-4-54 appears to decrease proliferation and increase apoptosis of treated tumors.
  • Synonyms
    SH-4-54 | SH 4-54 | SH4-54 | SH-454 | SH 454 | SH454.
  • Pathway
    JAK/STAT Signaling
  • Target
    STAT
  • Recptor
    STAT3|STAT5
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1456632-40-8
  • Formula Weight
    610.5921
  • Molecular Formula
    C29H27F5N2O5S
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C(O)C1=CC=C(N(CC2=CC=C(C3CCCCC3)C=C2)C(CN(C)S(=O)(C4=C(F)C(F)=C(F)C(F)=C4F)=O)=O)C=C1
  • Chemical Name
    Benzoic acid, 4-[[(4-cyclohexylphenyl)methyl][2-[methyl[(2,3,4,5,6-pentafluorophenyl)sulfonyl]amino]acetyl]amino]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Haftchenary S, et al. ACS Med Chem Lett. 2013 Sep 8;4(11):1102-7. 2. Arpin CC, et al. Mol Cancer Ther. 2016 May;15(5):794-805. 3. Linher-Melville K, et al. PLoS One. 2016 Aug 11;11(8):e0161202.
molnova catalog
related products
  • AC-4-130

    AC-4-130 is a novel, potent STAT5 SH2 domain inhibitor, binds to and efficiently blocks STAT5 activation and subsequent transcriptional activity.

  • Pomstafib-2

    The pivaloyloxymethyl ester prodrug of Stafib-2, which is a potent, selective STAT5b inhibitor with Ki of 9 nM.

  • PM-43I

    PM-43I is a selective inhibitor of STAT5/6 Src Homology 2 (SH2) domain.